BioCentury | Oct 23, 2020
Finance
Sarepta joins investor trio in Aavanti’s $107M series A round to develop gene therapy for Friedreich’s ataxia
...the series A round, AavantiBio received backing from Italian patient advocacy group GoFAR and the Muscular Dystrophy Association...